Nicholas J. Vogelzang mostly deals with Internal medicine, Surgery, Oncology, Prostate cancer and Cancer. His Internal medicine research integrates issues from Gastroenterology and Endocrinology. His Surgery research includes elements of Placebo, Carcinoma and Mesothelioma.
His Oncology research incorporates themes from Combination chemotherapy, Randomized controlled trial, Pathology, Proportional hazards model and Metastasis. The various areas that Nicholas J. Vogelzang examines in his Prostate cancer study include Hazard ratio, Prostate, Docetaxel and Urology. His study looks at the relationship between Chemotherapy and fields such as Atezolizumab, as well as how they intersect with chemical problems.
Nicholas J. Vogelzang spends much of his time researching Internal medicine, Oncology, Prostate cancer, Surgery and Chemotherapy. His Internal medicine study deals with Gastroenterology intersecting with Adverse effect. His work in Oncology addresses subjects such as Sipuleucel-T, which are connected to disciplines such as Asymptomatic.
As a part of the same scientific study, Nicholas J. Vogelzang usually deals with the Prostate cancer, concentrating on Urology and frequently concerns with Endocrinology. His studies in Surgery integrate themes in fields like Mesothelioma and Hazard ratio. As part of one scientific family, Nicholas J. Vogelzang deals mainly with the area of Chemotherapy, narrowing it down to issues related to the Toxicity, and often Pharmacology.
His scientific interests lie mostly in Internal medicine, Oncology, Prostate cancer, In patient and Cancer research. His study in Docetaxel, Adverse effect, Clinical trial, Chemotherapy and Renal cell carcinoma falls within the category of Internal medicine. His research investigates the link between Adverse effect and topics such as Gastroenterology that cross with problems in Placebo.
Bladder cancer, Hazard ratio and Mesothelioma is closely connected to Randomized controlled trial in his research, which is encompassed under the umbrella topic of Clinical trial. His Oncology research is multidisciplinary, incorporating elements of Pembrolizumab, Urothelial cancer, Circulating tumor cell and Phases of clinical research. Nicholas J. Vogelzang combines subjects such as Rucaparib and Asymptomatic with his study of Prostate cancer.
Internal medicine, Prostate cancer, Oncology, Cancer research and Docetaxel are his primary areas of study. His study in Internal medicine focuses on Adverse effect, Clinical endpoint, Chemotherapy, Atezolizumab and Clear cell renal cell carcinoma. His Adverse effect research incorporates elements of Gastroenterology and Carcinoma.
His study in Prostate cancer is interdisciplinary in nature, drawing from both Survival rate, Circulating tumor cell and Hazard ratio. The study incorporates disciplines such as Pembrolizumab, Regimen, Clinical trial and Asymptomatic in addition to Oncology. His work deals with themes such as Androgen and Urology, which intersect with Clinical trial.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Nicholas J. Vogelzang;James J. Rusthoven;James Symanowski;Claude Denham.
Journal of Clinical Oncology (2003)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker;S. Nilsson;S. Nilsson;D. Heinrich;S. I. Helle.
The New England Journal of Medicine (2013)
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
H. Barton Grossman;Ronald B. Natale;Catherine M. Tangen;V.O. Speights.
The New England Journal of Medicine (2003)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet.
The New England Journal of Medicine (2017)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh.
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Christopher J. Sweeney;Yu Hui Chen;Michael Carducci;Glenn Liu.
The New England Journal of Medicine (2015)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Thomas Powles;Ignacio Durán;Michiel S van der Heijden;Yohann Loriot.
The Lancet (2017)
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
Philip W. Kantoff;Susan Halabi;Mark Conaway;Joel Picus.
Journal of Clinical Oncology (1999)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis.
Lancet Oncology (2012)
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Jyoti D. Patel;Lada Krilov;Sylvia Adams;Carol Aghajanian.
Journal of Clinical Oncology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: